Fibrinogen levels are associated with bleeding in patients with primary immune thrombocytopenia

References

• Cooper N, Bussel J. The pathogenesis of immune thrombocytopaenic purpura. Br J Haematol 2006;133:364–374. doi:10.1111/j.1365-2141.2006.06024.x.
   PubMed Web of Science ®Google Scholar
• Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, Chong BH, Cines DB, Gernsheimer TB, Godeau B, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010;115:168–186. doi:10.1182/blood-2009-06-225565.
   PubMed Web of Science ®Google Scholar
• Schoonen WM, Kucera G, Coalson J, Li L, Rutstein M, Mowat F, Fryzek J, Kaye JA. Epidemiology of immune thrombocytopenic purpura in the General Practice Research Database. Br J Haematol 2009;145:235–244. doi:10.1111/j.1365-2141.2009.07615.x.
   PubMed Web of Science ®Google Scholar
• Portielje JE, Westendorp RG, Kluin-Nelemans HC, Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001;97:2549–2554. doi:10.1182/blood.V97.9.2549.
   PubMed Web of Science ®Google Scholar
• Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH, Cooper N, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009;113:2386–2393. doi:10.1182/blood-2008-07-162503.
   PubMed Web of Science ®Google Scholar
• Piel-Julian ML, Mahevas M, Germain J, Languille L, Comont T, Lapeyre-Mestre M, Payrastre B, Beyne-Rauzy O, Michel M, Godeau B, et al. Risk factors for bleeding, including platelet count threshold, in newly diagnosed immune thrombocytopenia adults. J Thromb Haemost 2018;16:1830–1842. doi:10.1111/jth.14227.
   PubMed Web of Science ®Google Scholar
• Michel M, Rauzy OB, Thoraval FR, Languille L, Khellaf M, Bierling P, Godeau B. Characteristics and outcome of immune thrombocytopenia in elderly: results from a single-center case-controlled study. Am J Hematol 2011;86:980–984. doi:10.1002/ajh.22170.
   PubMed Web of Science ®Google Scholar
• Greene LA, Chen S, Seery C, Imahiyerobo AM, Bussel JB. Beyond the platelet count: immature platelet fraction and thromboelastometry correlate with bleeding in patients with immune thrombocytopenia. Br J Haematol 2014;166:592–600. doi:10.1111/bjh.12929.
   PubMed Web of Science ®Google Scholar
• Spahr JE, Rodgers GM. Treatment of immune-mediated thrombocytopenia purpura with concurrent intravenous immunoglobulin and platelet transfusion: a retrospective review of 40 patients. Am J Hematol 2010;83:122–125. doi:10.1002/ajh.21060.
   Web of Science ®Google Scholar
• Looney MR, Gropper MA, Matthay MA. Transfusion-related acute lung injury: a review. Chest 2004;126:249–258. doi:10.1378/chest.126.1.249.
   PubMed Web of Science ®Google Scholar
• Uhl L, Assmann SF, Hamza TH, Harrison RW, Gernsheimer T, Slichter SJ. Laboratory predictors of bleeding, and effect of platelet and RBC transfusions on bleeding outcomes, in the PLADO Trial. Blood 2017;130:1247–1258. doi:10.1182/blood-2017-01-757930.
   PubMed Web of Science ®Google Scholar
• Jeong SM, Song JG, Seo H, Choi JH, Jang DM, Hwang GS. Quantification of both platelet count and fibrinogen concentration using maximal clot firmness of thromboelastometry during liver transplantation. Transplant Proc 2015;47:1890–1895. doi:10.1016/j.transproceed.2015.02.019.
   PubMed Web of Science ®Google Scholar
• Velik-Salchner C, Haas T, Innerhofer P, Streif W, Nussbaumer W, Klingler A, Klima G, Martinowitz U, Fries D. The effect of fibrinogen concentrate on thrombocytopenia. J Thromb Haemost 2010;5:1019–1025. doi:10.1111/j.1538-7836.2007.02481.x.
   Google Scholar
• Wagner CL, Mascelli MA, Neblock DS, Weisman HF, Coller BS, Jordan RE. Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets. Blood 1996;88:907–914. doi:10.1007/s002770050209.
   PubMed Web of Science ®Google Scholar
• Cox AD, Devine DV. Factor XIIIa binding to activated platelets is mediated through activation of glycoprotein IIb-IIIa. Blood 1994;83:1006–1016. doi:10.1016/0955-3886(94)90043-4.
   PubMed Web of Science ®Google Scholar
• Lang T, Johanning K, Metzler H, Piepenbrock S, Solomon C, Rahe-Meyer N, Tanaka KA. The effects of fibrinogen levels on thromboelastometric variables in the presence of thrombocytopenia. Anesth Analg 2009;108:751–758. doi:10.1213/ane.0b013e3181966675.
   PubMed Web of Science ®Google Scholar
• Misgav M, Shenkman B, Budnik I, Einav Y, Martinowitz U. Differential roles of fibrinogen and von Willebrand factor on clot formation and platelet adhesion in reconstituted and immune thrombocytopenia. Anesth Analg 2011;112:1034–1040. doi:10.1213/ANE.0b013e318212fffc.
   PubMed Web of Science ®Google Scholar
• Larsen OH, Stentoft J, Radia D, Ingerslev J, Sorensen B. Combination of recombinant factor VIIa and fibrinogen corrects clot formation in primary immune thrombocytopenia at very low platelet counts. Br J Haematol 2013;160:228–236. doi:10.1111/bjh.12118.
   PubMed Web of Science ®Google Scholar
• Shenkman B, Einav Y, Livnat T, Budnik I, Martinowitz U. In vitro evaluation of clot quality and stability in a model of severe thrombocytopenia: effect of fibrinogen, factor XIII and thrombin-activatable fibrinolysis inhibitor. Blood Transfus 2014;12:78–84. doi:10.2450/2013.0068-13.
   PubMed Web of Science ®Google Scholar
• Blome M, Isgro F, Kiessling AH, Skuras J, Haubelt H, Hellstern P, Saggau W. Relationship between factor XIII activity, fibrinogen, haemostasis screening tests and postoperative bleeding in cardiopulmonary bypass surgery. Thromb Haemost 2005;93:1101–1107. doi:10.1160/TH04-12-0799.
   PubMed Web of Science ®Google Scholar
• Rahemeyer N, Solomon C, Hanke A, Schmidt DS, Knoerzer D, Hochleitner G, Sørensen B, Hagl C, Pichlmaier M. Effects of fibrinogen concentrate as first-line therapy during major aortic replacement surgery: a randomized, placebo-controlled trial. Anesthesiology 2013;118:40–50. doi:10.1097/ALN.0b013e3182715d4d.
   PubMed Web of Science ®Google Scholar
• Rahe-Meyer N, Hanke A, Schmidt DS, Hagl C, Pichlmaier M. Fibrinogen concentrate reduces intraoperative bleeding when used as first-line hemostatic therapy during major aortic replacement surgery: results from a randomized, placebo-controlled trial. J Thorac Cardiovasc Surg 2013;145:S178–S185. doi:10.1016/j.jtcvs.2012.12.083.
   PubMed Web of Science ®Google Scholar
• Ranucci M, Baryshnikova E, Ranucci M, Silvetti S, Surgical, Clinical Outcome Research G. Fibrinogen levels compensation of thrombocytopenia-induced bleeding following cardiac surgery. Int J Cardiol 2017;249:96–100. doi:10.1016/j.ijcard.2017.09.157.
   PubMed Web of Science ®Google Scholar
• Cristina S, Niels RM. Fibrinogen concentrate as first-line therapy in aortic surgery reduces transfusion requirements in patients with platelet counts over or under 100×10(9)/L. Blood Transfus 2015;13:248–254. doi:10.2450/2014.0147-14.
   PubMed Web of Science ®Google Scholar
• Fujita A, Sakai R, Matsuura S, Yamamoto W, Ohshima R, Kuwabara H, Okuda M, Takahashi T, Ishigatsubo Y, Fujisawa S. A retrospective analysis of obstetric patients with idiopathic thrombocytopenic purpura: a single-center study. Int J Hematol 2010;92:463–467. doi:10.1007/s12185-010-0684-8.
   PubMed Web of Science ®Google Scholar
• Favaloro EJ, Lippi G. Hemostasis and thrombosis: methods and protocols. In: JM W, editor. Methods in molecular biology. New York, NY 10013, USA: Springer Nature; 2017. p. 533–559.
   Google Scholar
• Alvarez-Roman MT, Fernandez-Bello I, Jimenez-Yuste V, Martin-Salces M, Arias-Salgado EG, Rivas Pollmar MI, Justo Sanz R, Butta NV. Procoagulant profile in patients with immune thrombocytopenia. Br J Haematol 2016;175:925–934. doi:10.1111/bjh.14412.
   PubMed Web of Science ®Google Scholar
• Gunduz E, Akay OM, Bal C, Gulbas Z. Can thrombelastography be a new tool to assess bleeding risk in patients with idiopathic thrombocytopenic purpura? Platelets 2011;22:516–520. doi:10.3109/09537104.2011.571317.
   PubMed Web of Science ®Google Scholar
• Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH, Cooper N. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009;113:2386. doi:10.1182/blood-2008-07-162503.
   PubMed Web of Science ®Google Scholar
• Khellaf M, Michel M, Schaeffer A, Bierling P, Godeau B. Assessment of a therapeutic strategy for adults with severe autoimmune thrombocytopenic purpura based on a bleeding score rather than platelet count. Haematologica 2005;90:829–832. doi:10.1016/j.exphem.2005.03.004.
   PubMed Web of Science ®Google Scholar
• Ranucci M, Baryshnikova E, Crapelli GB, Rahe-Meyer N, Menicanti L, Frigiola A. Randomized, double-blinded, placebo-controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. J Am Heart Assoc 2015;4:e002066–e002066. doi:10.1161/JAHA.115.002066.
   PubMed Web of Science ®Google Scholar
• Fries D, Krismer A, Klingler A, Streif W, Klima G, Wenzel V, Haas T, Innerhofer P. Effect of fibrinogen on reversal of dilutional coagulopathy: a porcine model. Br J Anaesth 2005;95:172–177. doi:10.1093/bja/aei160.
   PubMed Web of Science ®Google Scholar
• Tsuda H, Tsuji T, Tsuji M, Yamasaki H. Life-threatening bleeding episodes in primary immune thrombocytopenia: a single-center retrospective study of 169 inpatients. Ann Hematol 2017;96:1915–1920. doi:10.1007/s00277-017-3095-6.
   PubMed Web of Science ®Google Scholar
• Moulis G, Palmaro A, Montastruc JL, Godeau B, Lapeyre-Mestre M, Sailler L. Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France. Blood 2014;124:3308. doi:doi:10.1182/blood-2014-05-578336.
   PubMed Web of Science ®Google Scholar
• Bizzoni L, Mazzucconi MG, Gentile M, Santoro C, Bernasconi S, Chiarotti F, Foà R, Mandelli F. Idiopathic thrombocytopenic purpura (ITP) in the elderly: clinical course in 178 patients. Eur J Haematol 2010;76:210–216. doi:10.1111/j.1600-0609.2005.00602.x.
   Google Scholar
• John D, Sarah L, Thompson SG, Lowe GDO, Rory C, Kostis JB, Wilson AC, Folsom AR, Wu K, Benderly M. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. Jama 2005;294:1799–1809. doi:10.1001/jama.294.14.1799.
   PubMed Web of Science ®Google Scholar
• Lowe GD, Lee AJ, Rumley A, Price JF, Fowkes FG. Blood viscosity and risk of cardiovascular events: the Edinburgh Artery Study. Br J Haematol 2015;96:168–173. doi:10.1046/j.1365-2141.1997.8532481.x.
   Google Scholar
• Sarpatwari A, Bennett D, Logie JW, Shukla A, Beach KJ, Newland AC, Sanderson S, Provan D. Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database. Haematologica 2010;95:1167–1175. doi:10.3324/haematol.2009.018390.
   PubMed Web of Science ®Google Scholar
• Ruggeri M, Tosetto A, Palandri F, Polverelli N, Mazzucconi MG, Santoro C, Gaidano G, Lunghi M, Zaja F, De Stefano V. Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment‐related risk factors. J Thromb Haemost 2014;12:1266–1273. doi:10.1111/jth.12636.
   PubMed Web of Science ®Google Scholar